OBJECTIVES: To project the potential economic impact of pandemic influenza mitigation strategies from a societal perspective in the United States. METHODS: We use a stochastic agent-based model to simulate pandemic influenza in the community. We compare 17 strategies: targeted antiviral prophylaxis (TAP) alone and in combination with school closure as well as prevaccination. RESULTS: In the absence of intervention, we predict a 50% attack rate with an economic impact of $187 per capita as loss to society. Full TAP (FTAP) is the most effective single strategy, reducing number of cases by 54% at the lowest cost to society ($127 per capita). Prevaccination reduces number of cases by 48% and is the second least costly alternative ($140 per capita). Adding school closure to FTAP or prevaccination further improves health outcomes but increases total cost to society by approximately $2700 per capita. CONCLUSION: FTAP is an effective and cost-saving measure for mitigating pandemic influenza.
OBJECTIVES: To project the potential economic impact of pandemic influenza mitigation strategies from a societal perspective in the United States. METHODS: We use a stochastic agent-based model to simulate pandemic influenza in the community. We compare 17 strategies: targeted antiviral prophylaxis (TAP) alone and in combination with school closure as well as prevaccination. RESULTS: In the absence of intervention, we predict a 50% attack rate with an economic impact of $187 per capita as loss to society. Full TAP (FTAP) is the most effective single strategy, reducing number of cases by 54% at the lowest cost to society ($127 per capita). Prevaccination reduces number of cases by 48% and is the second least costly alternative ($140 per capita). Adding school closure to FTAP or prevaccination further improves health outcomes but increases total cost to society by approximately $2700 per capita. CONCLUSION:FTAP is an effective and cost-saving measure for mitigating pandemic influenza.
Authors: Derek Weycker; John Edelsberg; M Elizabeth Halloran; Ira M Longini; Azhar Nizam; Vincent Ciuryla; Gerry Oster Journal: Vaccine Date: 2005-01-26 Impact factor: 3.641
Authors: M Elizabeth Halloran; Frederick G Hayden; Yang Yang; Ira M Longini; Arnold S Monto Journal: Am J Epidemiol Date: 2006-11-06 Impact factor: 4.897
Authors: Lisa A Prosser; G Thomas Ray; Megan O'Brien; Ken Kleinman; Jeanne Santoli; Tracy A Lieu Journal: Pediatrics Date: 2004-02 Impact factor: 7.124
Authors: Neil M Ferguson; Derek A T Cummings; Christophe Fraser; James C Cajka; Philip C Cooley; Donald S Burke Journal: Nature Date: 2006-04-26 Impact factor: 49.962
Authors: Luis R Carrasco; Vernon J Lee; Mark I Chen; David B Matchar; James P Thompson; Alex R Cook Journal: J R Soc Interface Date: 2011-02-04 Impact factor: 4.118
Authors: Elektra Szewczuk; Kiran Thapa; Terry Anninos; Kenneth McPhie; Geoff Higgins; Dominic E Dwyer; Keith K Stanley; Jonathan R Iredell Journal: BMC Infect Dis Date: 2010-05-11 Impact factor: 3.090